We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.73 | 1.87% | 39.80 | 40.12 | 39.58 | 39.63 | 3,064,146 | 01:00:00 |
From Jul 2022 to Jul 2024
0913 GMT - GSK PLC is among the most mentioned companies across news items over the past six hours, according to Factiva data, after the company reported a first-quarter beat and backed its 2023 guidance, although earnings and sales fell on year. The British pharma giant said that first-quarter sales were hit by lower Covid-19 solutions sales compared with the same quarter of 2022. Operating profit and earnings per share were lower due to the previous year's income benefit from the Gilead settlement and higher sales of Covid-19 treatment Xevudy. GSK's vaccine business beat expectations by 8% and best-selling shingles vaccine Shingrix came in line with consensus, analysts at UBS said in a note. Company consensus is expected to remain unchanged following the results, and shares are expected to react neutrally or slightly positively, UBS said. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
April 26, 2023 05:28 ET (09:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
